~~<i id='48AF51C0B8'><strike id='48AF51C0B8'><tt id='48AF51C0B8'><pre id='48AF51C0B8'></pre></tt></strike></i>~~

Home» knowledge» knowledge

knowledge

author：leisure time 2025-10-04 10:03:15 Page View：731

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Researchers explore possible ties between long Covid, menopause
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

knowledge

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

How climate

AdobeIn2003,duringEurope’sworstheatwaveincenturies,almost15,000peoplediedinFrance.Aboutthree-quarter

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Mass General totes up its waste in a move to tackle climate change

OnanAugustThursdayin2021,deepintothepandemic,twoMassachusettsGeneralHospitaldoctorsstoodgowned,glove